Share on facebook Share on Twitter Share on Google Plus Share This

Hypertrophic Cardiomyopathy Center
and Research Institute

Research + Clinical Trials

In addition to providing world-class care for patients with HCM and their family members, the Tufts Medical Center HCM Center is at the forefront of scientific clinical research aimed at improving diagnosis and management strategies for all patients with hypertrophic cardiomyopathy. Our team is currently involved in a variety of investigative research projects focused on identifying mechanisms of HCM disease expression which may ultimately lead to future therapies to improve the lives of our patients. In addition, we are a leading Center for clinical trials evaluating the efficacy of a number of recent novel drug therapies aimed at mitigating limiting symptoms in patients with HCM.  

At Tufts Medical Center, hypertrophic cardiomyopathy is a treatable genetic heart disease compatible with normal or extended longevity (often without the requirement of major treatments). Our national/international HCM Referral Center has established this principle for patients with this genetic disease over the past 15 years.

The HCM Center and Research Institute has achieved a particularly high level of clinical research activity, providing a model for contemporary diagnosis, natural history and clinical course and treatment of HCM which has resulted in low mortality and survival with high quality of life. These are the most important peer-reviewed published papers (with citations) from the last 5 years:

Maron BJ, Rowin EJ, Casey SA, Maron MS.  How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low morality: Shaped by 50 years of clinical research and practice.  JAMA Cardiol.  2016;1:98-105.

Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, Udelson JE, Maron MS, et al.  Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies.  J Am Coll Cardiol.  2015;65:1915-1928.

Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, Maron MS, et al.  Hypertrophic cardiomyopathy with left ventricular apical aneurysm:  Implications for risk stratification and management.  J Am Coll Cardiol 2017;69:761-773.

Maron MS, Maron BJ. Clinical impact of contemporary cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy.  Circulation 2015;132:292-8.

Semsarian C, Ingles J, Maron MS, Maron BJ.  New perspectives on the prevalence of hypertrophic cardiomyopathy.  J Am Coll Cardiol 2015;65:1249-54.

Rastegar H, Boll G, Rowin EJ, Dolan N, Carroll C, Udelson JE, Wang W, Carpino P, Maron BJ, Maron MS, Chen FY, et al. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Ann Cardiothorac Surg 2017;6:353-363.

Maron BJ, Maron MS, Rowin EJ.  Perspectives on the overall risk of living with hypertrophic cardiomyopathy.  Circulation.  2017; 135: 2317-2319.

Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy:  present and future, with translation into contemporary cardiovascular medicine.  J Am Coll Cardiol 2014;64:83-99.

Rowin EJ, Maron MS, Chan RH, Hausvater A, Wang W, Rastegar H, Maron BJ.  Interaction of adverse disease related pathways in hypertrophic cardiomyopathy.  Am J Cardiol, 2017; L23:2256-64.

Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ.  Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy.  Circulation, 2017; 136: 2420-36.

Rowin EJ, Orfanos A, Estes NAM, Wang W, Link MS, Maron MS, Maron BJ. Occurrence and natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomyopathy: AM J Cardiol, 2017; 119:1862-65.

Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Link MS, Bonow RO, Estes NAM, Maron MS.  Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities:  Task Force 3:  Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis:  A scientific statement from the American Heart Association and American College of Cardiology.  J Am Coll Cardiol.  2015; 66: 2362-2371.

Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS.  Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy.  Am J Cardiol. 2015; 166: 757-64

Maron MS, Hellawell JL, Lucove JC, Franzanek-Far R, Olivotto I.  Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States.  Am J Cardiol. 2016; 117:1651-54.

Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO.  Sudden deaths in young competitive athletes:  analysis of 1866 deaths in the United States, 1980-2006.  Circulation 2009; 119-1085-1092.

Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WI, Maron MS.  Risk Stratification and outcome of patients with hypertrophic cardiomyopathy over 60 years of age.  Circulation 2013;127:585-93.

Maron BJ, Rowin EJ, Casey SA, Lesser JR, Garberich RF, Maron MS.  Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies.  Circulation. 2016;133:62-73.

Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Estes NAM, et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.  JAMA.  2007;298:405-412.

Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haast T, Udelson JE, Rowin E, Maron MS.  Prognostic value of quantative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.  Circulation.  2014;130:484-495.

Maron MS, Kalsmith BM, Udelson JE, Li W, DeNofrio D.  Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy.  Circ Heart Fail 2010;3:574-9.

Rowin EJ, Maron BJ, Olivotto I, Maron MS.  Role of exercise testing in hypertrophic cardiomyopathy.  State-of-the art.  JACC Imag, Cardiovasc Img 2017; 10:1374-86.

Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, et al.  Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy.  J Am Coll Cardiol 2016;67:1399-409.

Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR, Maron BJ, Maron MS.  Mechanism of progressive heart failure and significance of pulmonary hypertension in obstructive hypertrophic cardiomyopathy.  Circ Heart Fail 2017;10:e003689.

Maron BJ, Maron MS.  Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.  Heart Rhythm.  2016;13:1155-1165.

Maron BJ, Maron MS. A discussion of contemporary nomenclature, diagnosis, imaging and management of patients with hypertrophic cardiomyopathy. Am J Cardiol. 2016; 118:1897-1907.

Maron MS, Xin W, Sims KB, Butler R, Haas TS, Rowin EJ, Desnick RJ, Maron BJ. Identification of Fabry disease in a tertiary referral cohort of patients with hypertrophic cardiomyopathy. Am J Med, 2017; pii 5002-9343 (17) 30939-7.

Maron BJ, Roberts WC. The father of septal myectomy for obstructive HCM who also had HCM: The unbelievable story. J Am Coll Cardiol. 2016; 67:2900-2903.

Maron MS, Rowin EJ, Maron BJ. How to image hypertrophic cardiomyopathy. Circ Cardiovasc Imaging, 2007; 10:piiECO5372

Maron BJ, Rowin EJ, Maron MS Braunwald E. Achieving extended longevity and quality of life for senior patients with hypertrophic cardiomyopathy. What is possible.  Am J Med, 2017; 130:1236-37.

Maron BJ, Nishimwia RA, Maron MS. Shared decision-making in HCM. Nat Rev Cardiol 2017; 14: 125-6.

Maron BJ. Saving lives one at a time. JAMA Cardiol 2016; 1: 387-8.

Maron BJ, Maron MS. The remarkable 50 years of imaging in HCM and how it has changed diagnosis and management: from m-mode echocardiography to CMR. JACC Cardiovasc Imag 2016; 9: 858-72.

Maron BJ. Historical perspectives on sudden death in young athletes with evolution over 35 years. Am J Cardiol 2015; 116: 1461-8.

Maron BJ, Rowin EJ, Casey SA, Garberich RF, Maron MS. What do patients with hypertrophic cardiomyopathy die from? Am J Cardiol 2016; 117:434-5.

Maron BJ. Importance + feasibility of creating hypertrophic cardiomyopathy centers in developing countries: the experience in India. Am J Cardiol 2015; 116: 332-4.

Link MS, Bockstall K, Weinstock J, Alsheikh-Ali AA, Semsarian C, Estes NAM, Spirito P, Haas TS, Rowin EJ, Maron MS. Ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy and defibrillators: triggers, treatment, and implications. J Cardiovas Electrophysiol 2017; 28: 531-7.

Rowin EJ, Maron BJ Agt P, Kiernan MS, Vest A, Costantino F, Maron MS, DeNofrio D. Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy. Am J Cardiol 2018; pii50002-9149 (18) 30112-7.

Wells S, Rowin EJ, Boll G, Rastergar H, Wang W, Marson MS, Maron BJ. Clinical profile of nonresponders to surgical myectomy with obstructive hypertrophic cardiomyopathy. Am J Med 2018; pii50002-9343 (18) 30021-4.

 
Sue Costa is the coordinator in the Hypertrophic Cardiomyopathy Center at Tufts Medical Center in downtown Boston, MA.

For an appointment, contact our HCM Center Coordinator Sue Costa. She will help you.

Phone: 617-636-8066 option 1 Email: scosta2@tuftsmedicalcenter.org

Father, son Cardiovascular Specialists, Barry and Martin Maron, spread the word that HCM is now a manageable disease at Tufts Medical Center in downtown Boston, MA.

The father-son duo that’s changing a cardiac narrative

Drs. Barry and Marty Maron want you to know something: HCM is now a treatable disease compatible with normal longevity and a good quality of life.

Read the article